A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Vericel Corporation VCEL

Strong broader-coverage candidate · Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments.

On FrontierLab's discovery record since 2026-07-13 (5 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Strong" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-21), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	23%
Gross margin	74.6%
Gross profits / assets	0.45
Rule of 40	29
Net margin	6%
Cash runway (months)	—
PEG	0.3
Price / sales	7

Quality checklist

✓ Revenue growth — 23% (pass ≥ 20%)
✓ Gross profits / assets — 0.45 (pass ≥ 0.33)
✓ Gross margin — 74.6% (pass ≥ 60%)
✓ Cash generation
~ Share dilution — 1.1%

Fundamentals — snapshot as of 2026-08-21

Stage	Established
Share issuance (YoY)	1.1% · modest issuance
Moat	—
TAM	—
P/E (trailing)	90
EPS (trailing)	$0.47
Burn multiple	—
Gross-margin trend (pts)	1.1
Cash / assets	0.32
Net debt / EBITDA	-0.9
Statements as of	Q2 FY2026 · filed 2026-07-30

Momentum context — a snapshot from 2026-08-21, not current

Price at surface	$42.11 (as of 2026-08-21)
52-week range	$28.95 – $49.32
% off 52-wk high	-14.6%
RSI (14)	37
Relative volume	1.2×

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-21 (end-of-day). How grades are computed →